Table 5 Subgroup analysis of patients with juxtapapillary PCV

From: Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy

  Treated Untreated
Total number of eyes 18 6
Median follow-up (range) 68.4 weeks (8.1 ± 116.0) 57.6 weeks (12.3–140.0)
Treatment
  Anti-VEGF and PDT 10 N/A
  PDT alone 6 N/A
  Anti-VEGF alone 2 N/A
Mean BCVA (± SD)
  Baseline 70.1 ± 8.7 letters 78.3 ± 14.4 letters
  Final visit 72.7 ± 8.4 letters 77.7 ± 10.1 letters
  pa 0.0740 0.5879
Mean BCVA change (± SD) 2.6 ± 5.5 letters −0.7 ± 15.1 letters
Mean CRT (± SD)
  Baseline 351.1 ± 110.8 μmb 289.0 ± 22.0 μm
  Final visit 242.3 ± 26.7 μmb 301.5 ± 59.4 μm
  pa 0.0004 0.8923
SRF and/or IRF (n eyes)
  Present at baseline 18 0
  Present at final visit 6 1
Subfoveal fluid (n eyes)
  Present at baseline 11 0
  Present at final visit 0 0
PED (n eyes)
  Present at baseline 16 1
  Improved at final visit 13 0
Status at final visit
  Discharged 2 2
  Monitoring 15 4
  Treat-and-extend 1 N/A
  1. N/A not applicable, BCVA best corrected visual acuity, SD standard deviation, CRT central retinal thickness, SRF subretinal fluid, IRF intraretinal fluid, PED pigment epithelial detachment
  2. aComparison of baseline and final BCVA and CRT values in the same treatment group (two-tailed Wilcoxon signed rank test)
  3. bMean CRT values calculated from n = 17 eyes